Norvasc, marketed under the brand name Amlodipine, is an antifungal medication primarily used to treat various fungal infections, including dermatologic conditions such as cryptococcal meningitis, urogenital infections, and genital candidiasis.
The Norvasc market is projected to experience significant growth over the coming years. As of 2023, the market size was valued at USD 9.6 billion and is expected to reach USD 16.4 billion by 2031, growing at a compound annual growth rate (CAGR) of 5.7% from 2024 to 2031[1][4].
The rising prevalence of mental health disorders such as schizophrenia, bipolar disorder, and depression is a major driver of the Norvasc market. Patients are more likely to receive effective treatments due to the increased awareness and understanding of these conditions[1][4].
Improvements in pharmaceutical formulations have brought more treatments available, which have enhanced the efficacy of Norvasc. These innovations have enabled patients to receive more convenient and accessible treatments, further expanding its market reach[4].
Recent regulatory changes, including decreased regulatory periods and revised approval and review requirements, have solidified the market as a whole. Market growth is expected to continue in the years to come, driven by increasing awareness of mental health conditions and advancements in pharmaceutical formulations[4].
The Norvasc market is geographically diverse, and it is expected to reach USD 2.81 billion by 2031, growing at a CAGR of 2.5% from 2024 to 2031[5].
North America is a major driver of the Norvasc market. The United States has the largest Norvasc market, and the second-largest, due to the presence of major U. S. states.
The Asia Pacific region is also a significant growth region, driven by the expansion of emerging economies and rising interest in therapeutic areas. The Asia Pacific countries are experiencing rapid economic advancements, such as China's pro-growth boom, and rising awareness about mental health disorders[5].
Norvasc, commonly known as Amlodipine, is a widely prescribed medication that targets multiple types of infections, including dermatologic conditions, hormonal disorders, and other fungal infections. The medication works by blocking the synthesis of ergosterol in the body, a key component of the cell wall of the fungus.
Unlike some other antifungal medications, Norvasc primarily targets skin and soft tissue infections, and it works by inhibiting the growth and spread of the fungi[3].
NEW YORK--
A study published in the New England Journal of Medicine on Tuesday has found that the drug
may reduce the risk of a heart attack or angina.
Researchers from the New England Journal of Medicine in Boston studied 2,700 people who had coronary artery disease or risk factors for the disease. They analyzed data from a study in the
. The findings were published March 15 in the
A heart attack in an elderly man who had been taking Norvasc for six months was linked to an increased risk of death by angina and another serious heart condition, which is an irregular heartbeat.
The study was published March 15 in the
It was the first study to examine the effect of Norvasc on a patient who had an angina attack or a heart condition.
The results were published in the Journal of the American College of Cardiology.
Dr. David A. Heilbrich, the study's lead author, said that the findings could help prevent a heart attack in men who are taking a medication known as calcium channel blockers.
However, he did not rule out other possible explanations for the finding.
The study's results were published March 15 in the Journal of the American College of Cardiology.
John L. Mott, a spokesman for the FDA, said that the agency has not approved Norvasc for the treatment of patients who have not previously received it. He declined to comment.
However, he did not rule out other possible explanations for the results.
The study was the first in the world to look for a possible risk factor for the development of a heart attack in an elderly man taking Norvasc.
According to the
, the study was published in the
The study was the first to look for a possible risk factor for the development of a heart attack in an elderly man taking Norvasc.
A. J. Lohr, a cardiologist at the Cleveland Clinic, said the results could help prevent a heart attack in men who are taking a medication known as calcium channel blockers.
David Heilbrich, the study's lead author, said that the findings could help prevent a heart attack in men who are taking a medication known as calcium channel blockers.
He added that he was not sure how much was found in Norvasc's drug-free drug list for the heart attack.
"These findings should be interpreted with caution, and we are not making any recommendations," Dr. Heilbrich said.
Steven Johnson, director of cardiovascular research at New York University School of Medicine, said the results "may not prove that Norvasc can reduce the risk of a heart attack or angina" but that "they may suggest that it may reduce the risk by reducing the likelihood of heart attacks or angina" in some men.
The study was published in the
,
, and
, both in the
The results of the study are in the journal JAMA Internal Medicine.
In a separate study conducted in the journal, the FDA and other regulatory agencies in the U. S. have not approved Norvasc for the treatment of patients who have not previously received it. Norvasc is known as amlodipine, but it is available as a generic drug called
It is not known whether Norvasc was added to the FDA's drug list for this reason.Norvasc is currently available in the United States and Canada as an oral tablet.
For more information about Norvasc and its drugs, visit the
and.The New England Journal of Medicineby
<
or.
The
included this article because it contains articles that are not included in the final version of this editorial.
Copyright © 2025 New England Journal of Medicine Inc.
All rights reserved.
O'Callaghan has the privilege of having had the opportunity to read the editorial staff'
that accompanied the study, which is available on
, and.
Xalmeds Online
Amlodipine Besylate (Norvasc) 5mg is a medication commonly used to manage high blood pressure (hypertension) and manage symptoms associated with these conditions like headache, dizziness, fainting, and shortness of breath. It works by blocking certain levels of angiotensin II receptors in the vascular system, which increases blood flow to the affected area. This increased blood flow helps to lower blood pressure and reduce swelling. It is important to note that this medication is only indicated for treating hypertension.
It should not be used in patients with a history of heart disease, kidney or liver disease, certain medications that are used for treating high blood pressure, or conditions like high cholesterol or high blood pressure. It is important to consult a healthcare professional before use, especially if you have a history of heart disease, high blood pressure, or a family history of heart disease, diabetes, or high cholesterol.
Amlodipine Besylate is only indicated for treating hypertension. It should be used under the guidance of a healthcare professional as prescribed by a doctor. It should not be administered to children under the age of 8 years old. It is important to note that this medication is not a medication that should not be taken by patients with a history of heart problems, kidney or liver diseases, certain medications that are used for treating high blood pressure, or conditions like high cholesterol or high blood pressure.
Show more FaxBrand NameAmlodipine
Show MoreAmlodipine Besylate (Norvasc) 5mg is a generic name for the medication amlodipine besylate used to manage high blood pressure and symptoms related to high blood pressure (hypertension) and symptoms associated with these conditions. It is a prescription medication that is typically prescribed by a healthcare professional for the treatment of high blood pressure (hypertension) in adults and adolescents from 6 years of age. It should be taken orally in a dose and duration as advised by the physician. It is important to follow the dosage and complete the full course of treatment as advised by the doctor. It is usually taken once daily at the same time each day.
A study of the efficacy of Norvasc and other antihypertensive drugs in the treatment of hypertension has been published by the European College of Cardiology and Hemophilia. The study was performed at a meeting on the topic in the European Congress of Cardiology. The study was conducted on a group of hypertensive patients treated with Norvasc (1 mg) or hydrochlorothiazide (60 mg). The patients were assessed for their ability to stop the hypertension by the H& Cl method. The mean duration of hypertension in the group treated with Norvasc (n = 22) or hydrochlorothiazide (n = 22) was significantly longer than that of the control group (n = 22). However, the duration of hypertension was shorter in the group treated with hydrochlorothiazide (n = 24) than that of the control group (n = 23). The mean difference in duration of hypertension was 6.5 months in the group treated with hydrochlorothiazide versus 6.6 months in the control group (p = 0.003). The study provides data that are consistent with the results obtained in a meta-analysis of randomized trials of the efficacy of hydrochlorothiazide for the treatment of hypertension. This study is the first to report the efficacy and safety of hydrochlorothiazide and other antihypertensive drugs in the treatment of hypertensive patients with hypertension, as compared to their control patients.
Etiology of hypertension:The most commonly prescribed antihypertensive drugs in the treatment of hypertension are Norvasc and hydrochlorothiazide. There are currently several medications available for the treatment of hypertension. Norvasc is the first line therapy for hypertension because it has been shown to be the most effective in all the trials. In addition, it has been shown to be very effective in patients who do not respond to other antihypertensive drugs. Norvasc is available as a single dose and is generally well tolerated by patients. Hydrochlorothiazide is a once-daily oral preparation of the same drug and is also effective in patients who have been on an antihypertensive drug for 6 months or more. The efficacy of both antihypertensive drugs and their antihypertensive drugs in the treatment of hypertension is not different.
The most common side effects of the antihypertensive drugs include dizziness, lightheadedness, headache, dyspepsia and nausea and vomiting. Some patients report a decrease in the frequency of urination. The most common side effects of the antihypertensive drugs include dizziness, lightheadedness, headache, dizziness and nausea and vomiting.
The drug is not recommended in patients who are hypersensitive to any of the active ingredients in Norvasc or hydrochlorothiazide. These patients are generally considered to be allergic to some of the active ingredients of Norvasc or hydrochlorothiazide. If any of the inactive ingredients in the drug are present in the blood, it is recommended to start the treatment with Norvasc. If this is not possible, the drug is contraindicated. There are currently several drugs available for the treatment of hypertension. Amlodipine is a calcium channel blocker and is approved for the treatment of hypertension.
Some patients with hypertension have been using an antihypertensive drug to control the blood pressure. In addition, the use of antihypertensive drugs is also not recommended in patients with high blood pressure who are not at a high risk for cardiovascular disease or who are taking other blood pressure medications, such as diuretics or ACE inhibitors. This is because the combination of the two drugs has an additive effect on the blood pressure levels and the combined effect is not expected to result in a clinically significant reduction in blood pressure. Patients with these risk factors may also be advised to use a combination of antihypertensive drugs. Lisinopril is a diuretic and is approved for the treatment of hypertension. Norvasc is a calcium channel blocker and is approved for the treatment of hypertension.
Stade de France Pharmacy